Author(s)Abou-Alfa GK, Meyer T, Cheng AL, et al. Cabozantinib in patients with advanced, progressing hepatocellular carcinoma. N Engl J Med. 2018, 379(1):54-63. doi: 10.1056/NEJMoa1717002. This phase ...

Phase II study of the oral hypoxia-inducible factor 2α (HIF-2 α) inhibitor MK-6482 in combination with cabozantinib in patients with advanced clear cell renal cell carcinoma (ccRCC). Background: C ...

COPENHAGEN — First-line treatment of metastatic kidney cancer could be set for change, with new results showing that the oral tyrosine kinase inhibitor cabozantinib (Cabometyx, Exelixis) significantly ...

Exelixis reported $515.2M in net product revenues in Q4'24, a 20% increase over net product revenues for Q4'23. EXEL's 2025 total revenue guidance is flat at $2.15B-$2.25B, although that doesn't model ...

Patients with advanced kidney cancer live for nearly twice as long without their disease progressing if they are treated with cabozantinib, a drug that inhibits the action of tyrosine kinases -- ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Cabozantinib (XL184) Phase 2 Data Demonstrate Encouraging Clinical Activity in Patients with Castration-Resistant Prostate Cancer High rates of complete or partial bone scan resolution (85%), pain ...

Long-term results show sustained benefit from the immunotherapy-TKI combination for patients with metastatic renal cell carcinoma regardless of risk profile or PD-L1 status. Patients receiving ...

Exploring Spatial-Temporal Changes in 18F-Sodium Fluoride PET/CT and Circulating Tumor Cells in Metastatic Castration-Resistant Prostate Cancer Treated With Enzalutamide We assessed the safety and ...

Please provide your email address to receive an email when new articles are posted on . First-line cabozantinib reduced tumor size among patients with radioactive iodine-refractory differentiated ...

ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced that COSMIC-313 met its primary endpoint, demonstrating significant improvement in progression-free survival (PFS) at ...